119 related articles for article (PubMed ID: 32949584)
1. Fungal mycotoxin penisuloxazin A, a novel C-terminal Hsp90 inhibitor and characteristics of its analogues on Hsp90 function related to binding sites.
Dai J; Zhu M; Qi X; Wang Y; Li H; Tang S; Wang Q; Chen A; Liu M; Gu Q; Li D; Li J
Biochem Pharmacol; 2020 Dec; 182():114218. PubMed ID: 32949584
[TBL] [Abstract][Full Text] [Related]
2. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
[TBL] [Abstract][Full Text] [Related]
3. Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.
Song X; Zhao Z; Qi X; Tang S; Wang Q; Zhu T; Gu Q; Liu M; Li J
Oncotarget; 2015 Mar; 6(7):5263-74. PubMed ID: 25742791
[TBL] [Abstract][Full Text] [Related]
4. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation.
Zhu S; Shen Q; Gao Y; Wang L; Fang Y; Chen Y; Lu W
J Med Chem; 2020 May; 63(10):5421-5441. PubMed ID: 32352777
[TBL] [Abstract][Full Text] [Related]
6. Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.
Wang W; Liu Y; Zhao Z; Xie C; Xu Y; Hu Y; Quan H; Lou L
Cancer Sci; 2016 Jun; 107(6):782-90. PubMed ID: 27002306
[TBL] [Abstract][Full Text] [Related]
7. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
Sharp SY; Prodromou C; Boxall K; Powers MV; Holmes JL; Box G; Matthews TP; Cheung KM; Kalusa A; James K; Hayes A; Hardcastle A; Dymock B; Brough PA; Barril X; Cansfield JE; Wright L; Surgenor A; Foloppe N; Hubbard RE; Aherne W; Pearl L; Jones K; McDonald E; Raynaud F; Eccles S; Drysdale M; Workman P
Mol Cancer Ther; 2007 Apr; 6(4):1198-211. PubMed ID: 17431102
[TBL] [Abstract][Full Text] [Related]
9. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
11. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 C-terminal inhibitor PNSA promotes anticancer immunology of CD8
Zhang A; Li M; Wang Y; Xiong Y; Zhu T; Qi X; Li J
Int Immunopharmacol; 2023 Aug; 121():110471. PubMed ID: 37356120
[TBL] [Abstract][Full Text] [Related]
13. Tubocapsenolide A targets C-terminal cysteine residues of HSP90 to exert the anti-tumor effect.
Zhu D; Li S; Chen C; Wang S; Zhu J; Kong L; Luo J
Pharmacol Res; 2021 Apr; 166():105523. PubMed ID: 33667688
[TBL] [Abstract][Full Text] [Related]
14. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Moses MA; Henry EC; Ricke WA; Gasiewicz TA
Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
16. A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone.
Yamada S; Ono T; Mizuno A; Nemoto TK
Eur J Biochem; 2003 Jan; 270(1):146-54. PubMed ID: 12492485
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
[TBL] [Abstract][Full Text] [Related]
19. FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.
Ye M; Huang W; Wu WW; Liu Y; Ye SN; Xu JH
Oncotarget; 2017 Feb; 8(9):15364-15376. PubMed ID: 28157708
[TBL] [Abstract][Full Text] [Related]
20. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]